[Editor's note: This version of the original story reflects the corrected effective date of Dec. 14 that was announced by DEA Nov. 16 (80 Fed. Reg. 70680)]. Eluxadoline, a drug recently approved for treatment of irritable bowel syndrome with diarrhea, will be placed in Schedule IV effective Dec. 14, according to the Drug Enforcement Administration. The final rule is expected to b... Read More